Darovasertib, a novel treatment for metastatic uveal melanoma
Frontiers in Pharmacology · 28.07.2023 · 14
DOI: 10.3389/fphar.2023.1232787 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.07.2023. Verfasst von Lei Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May 2022. Primary uveal melanoma has a high risk of progressing to metastatic uveal melanoma, with a poor prognosis. The activation of the PKC and mitogen-activated protein kinase pathways play an essential role in the pathogenesis of uveal melanoma, and mutations in the G protein subunit alpha q (GNAQ), and G protein subunit alpha11 (GNA11) genes are considered early events in the development of uveal melanoma. Compared to other PKC inhibitors, such as sotrastaurin and enzastaurin, darovasertib is significantly more potent in inhibiting conventional (α, β) and novel (δ, ϵ, η, θ) PKC proteins and has a better tolerability and safety profile. Current Phase I/II clinical trials indicated that darovasertib, combined with the Mitogen-activated protein kinase/Extracellular (MEK) inhibitors, binimetinib or crizotinib, produced a synergistic effect of uveal melanoma. In this article, we summarize the development of drugs for treating uveal melanomas and discuss problems associated with current treatments. We also discuss the mechanism of action, pharmacokinetic profile, adverse effects, and clinical trial for darovasertib, and future research directions for treating uveal melanoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
- School of Pharmacy, Weifang Medical University, Weifang, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, United States.
- Stuyvesant High School, New York, NY, United States.
- Ganzhou Key Laboratory of Hematology, Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Zitieren
APA
Cao, L., Chen, S., Sun, R., Ashby, C. R., Wei, L., Huang, Z., & Chen, Z. S. (2023). Darovasertib, a novel treatment for metastatic uveal melanoma. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1232787
Vancouver
Cao L, Chen S, Sun R, Ashby CR, Wei L, Huang Z, et al. Darovasertib, a novel treatment for metastatic uveal melanoma. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1232787
BibTeX
@article{Cao2023,
author = {Cao, Lei and Chen, Shuzhen and Sun, Rainie and Ashby, Charles R and Wei, Liuya and Huang, Zoufang and Chen, Zhe-Sheng},
title = {Darovasertib, a novel treatment for metastatic uveal melanoma},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1232787}
}
EUVIMED